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Summary Three intraperitoneal human ovarian cancer xenografts (OS, HU, and LA) were used to assess the
antitumour activity of intraperitoneal therapy with liposome encapsulated MTP-PE. MTP-PE led to significant
prolongation of survival in all three xenograft models, but with varying efficacy. In one tumour model (OS),
80% of mice were cured of tumour by twice weekly therapy for 4 weeks, whereas in another xenograft model
(LA), the median survival time was approximately doubled compared to PBS injected and placebo liposome
injected controls (median survivals: 30 vs 62.5 days respectively). The antitumour efficacy of MTP-PE did not
correlate with the extent of peritoneal neutrophil infiltration after intraperitoneal therapy. Combined therapy
with liposome encapsulated MTP-PE and recombinant murine granulocyte-macrophage colony stimulating
factor led to increased survival of mice bearing the LA and HU xenografts, compared to tumour bearing mice
treated with either agent singly.
Liposome encapsulated muramyl dipeptide (MDP) has been
shown to activate macrophages to a tumouricidal state (Sone
& Fidler 1980). A lipophilic derivative of MDP, muramyl
tripeptide phosphoethanolamine (MTP-PE), is more
efficiently incorporated into liposomes and is approximately
2.5 times as potent as the parent molecule in generating
tumouricidal activity in macrophages (Sone et al., 1986).
Systemic administration of liposome encapsulated MTP-PE
leads to activation of macrophages in visceral tissues such as
the liver and lung (Xu & Fidler 1984). This has been related
to the ability of MTP-PE to reduce tumour burden at these
sites in syngeneic murine tumour models (Fidler et al., 1981;
Phillips et al., 1985; Talmadge et al., 1986). As cells of the
monocyte-macrophage lineage constitute a major population
of cells in the peritoneal cavity, we speculated that injection
of liposome-encapsulated MTP-PE into this site would be an
efficient way to activate these cells to kill tumours in the
vicinity. Human ovarian cancer characteristically spreads
within the confines of the peritoneal cavity, and therefore
represents a relevant tumour for treatment by intra-
peritoneally administered antitumour therapies.
In this paper we describe the results of treating intra-
peritoneal human ovarian cancer xenografts in nude mice
with intraperitoneal administrations of liposome encap-
sulated MTP-PE. In addition, the effect of simultaneous
administrations of recombinant murine granulocyte-
macrophage colony stimulating factor (muGM-CSF) was
studied. Intraperitoneal administration of muGM-CSF has
been shown to increase the number of peritoneal macro-
phages (Metcalf et al., 1987), and enhance macrophage
phagocytosis and tumour killing (Grabstein et al., 1986; Met-
calf et al., 1987).
The results suggest that intracavitary therapy with
liposome encapsulated MTP-PE may offer a new therapeutic
modality for human ovarian cancer, and that the therapeutic
effect can be potentiated by recombinant muGM-CSF in
these xenograft models.
Methods and materials
Xenografts and mice
6-12 week old specific pathogen free athymic (nu/nu) female
mice of mixed genetic background were used. Ovarian cancer
xenografts OS, HU, and LA were established from primary
human tumours as described previously (Ward et al., 1987).
The OS and HU tumours were taken from 51 year old and
23 year old patients at the time of the first laparotomy
respectively. Both the OS and HU tumours were moderately
differentiated serous cystadenocarcinomas. The LA xenograft
was established from a primary poorly differentiated
mucinous cystadenocarcinoma in a 71 year old patient. All
three tumour xenografts retained the histological and
immunophenotypic characteristics of the original primary
tumours. The OS xenograft was used between passages
12-35, HU between passages 19-27, and LA between pas-
sages 1-12. The xenografts were stable in their growth char-
acteristics between the passages listed. The LA xenograft,
however, started to exhibit a more rapid growth rate after
passage 32, and in one experiment this aggressive tumour
was used to assess the therapeutic effect of MTP and muGM-
CSF.
Liposome encapsulated MTP-PE
Liposome encapsulated MTP-PE was provided by Dr I.J.
Fidler (University of Texas) for initial studies, and then by
Ciba-Geigy (Basel, Switzerland). The dry lyophilate was pro-
vided in vials as 175 mg phosphatidylcholine, 75 mg phos-
phatidylserine and 1 mg MTP-PE. The lyophilate was recon-
stituted in 5 ml phosphate buffered saline (PBS), and
vortexed for 1 min (Spinmix, Gallenkamp). This was further
diluted in PBS, to give a MTP-PE concentration of
66.7 ig ml-' (20 1tmol ml-'). 0.5 ml (10 tmol MTP-PE) of
this was used per i.p. injection. Liposomes of the same lipid
constitution containing PBS only were prepared identically.
muGM-CSF
Recombinant murine GM-CSF (rMu muGM-SCF) was pro-
vided by Dr J. Mermod (Glaxo, Geneva, Switzerland). The
muGM-CSF was diluted in PBS/BSA (3 mg ml-') to a con-
centration of 1 yg ml-'. One hundred t1l (100 ng) of this was
used per i.p. injection, as this dose has been shown to lead to
an increase in the peritoneal cell numbers in mice (Metcalf,
1987). The muGM-CSF was tested on a proliferation assay
with the murine cell line NFS-60. The activity of the muGM-
Correspondence: S.T.A. Malik.
Received 28 August 1990; and in revised form I November 1990.
Br. J. Cancer (1991), 63, 399-403 17" Macmillan Press Ltd., 1991400 S.T.A. MALIK et al.
CSF was 2.7 x 107 U mg-'. The endotoxin concentration of
the muGM-CSF preparation was less than 10 EU mg-'
(LAL assay).
Treatment protocols
Ascitic xenografts were obtained by peritonal aspiration from
nude mice previously injected with the respective xenografts.
The tumours were diluted in an equal volume of RPMI 1640,
and 0.2 ml of the resulting suspension (approximately 1 x 106
cells) injected intraperitoneally per mouse. Seven days after
intraperitoneal injection of tumour xenografts, intra-
peritoneal injection of MTP-PE containing or placebo
liposomes, given twice a week for 4 weeks was begun (eight
mice per treatment group). In some experiments muGM-CSF
was injected twice daily starting 7 days after tumour injection
and continued for 4 weeks, with or without twice weekly
liposome encapsulated MTP-PE for the same duration.
Tumour bearing mice were killed when they developed a
tumour burden that would lead to death in 24 h, as estab-
lished from previous experiments.
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Analysis ofperitoneal cellpopulations
Peritoneal cell populations were analysed 1, 2 and 7 days
after injection of PBS, placebo liposomes, or liposome-
encapsulated MTP-PE in control (non-tumour bearing) mice,
and mice injected 7 days previously with the HU xenograft.
Three mice were killed from each group at the given time
points, and the peritoneal cavity lavaged with 2 ml Ca2+ and
Mg21 free PBS. Tumour clumps were allowed to sediment
(1-2 min) and the supernatant analysed. The total cell count
was determined, and cytospin preparations were stained with
'Difquik' (Merck & Dade). At least 200 cells were counted,
and the percentage of polymorphonuclear neurophil leu-
cocytes calculated.
Immunohistology
Acetone fixed cytospin preparations (Shandon Cytospin,
Runcorn, UK), were stained for the expression of the tumour
associated antigen HMFG2 using a standard immunoperoxi-
dase method (Hsu et al., 1981).
Statistical analysis
Comparison of survival data was conducted using the Mann-
Whitney U test, and Students paired t-test was used to
compare analysis of peritoneal cell populations.
Results
Therapy with liposome-encapsulated MTP-PE
Survival curves of mice injected with the three intraperitoneal
xenografts are shown in Figure 1. The figures for the LA and
OS xenografts represent the composite results of two separate
experiments (n = 16 per group), and one experiment with the
HU xenograft (n = 8 per group). Liposome encapsulated.
MTP-PE significantly prolonged the survival of mice bearing
the LA and OS xenografts compared to PBSA or placebo
liposome injected mice (P <0.1). In mice injected with the
HU xenograft placebo liposomes also prolonged survival of
mice compared to controls (P <0.5). Although the median
survival and the number of mice surviving greater than 60
days was greater in the groups injected with liposome encap-
sulated MTP-PE compared to the groups injected with the
placebo liposomes, the difference in the survival between the
two groups was not statistically significant in the HU xeno-
graft.
The OS xenograft tumour most sensitive to the effects of
MTP-PE. Analysis of peritoneal lavage fluid from mice with
the OS tumour as early as 3 days after injection of placebo
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Figure 1 Survival of mice bearing the a, OS (n = 16), b, LA
(n = 16), and c, HU (n = 8) xenografts. Dotted lines = PBS, open
circles = placebo lipsomes, closed circles = MTP-PE liposomes.
liposomes showed many viable clumps of tumour cells
amongst the host peritoneal cells (Figure 2a). In MTP-PE
treated mice however, very few tumour cells were seen, and
the tumour cells present were surrounded by clusters of host
cells that were morphologically macrophages (Figure 2b).
Post-mortem examination of mice surviving beyond 100 days
in two separate experiments with different passages (12 and
35) of the OS tumour, revealed no macroscopic or micro-
scopic evidence of tumour, representing an overall cure rate
of 80%. Mice bearing HU and LA xenografts eventually
succumbed to large intraperitoneal and ascites.
Peritoneal cellpopulations in mice
The baseline number of peritoneal cells in the tumour bear-
ing mice was greater than in control mice (P <.05). Injection
of placebo liposomes and liposome encapsulated MTP-PE
led to a marked increase in the number of peritoneal cells in
both control and tumour bearing mice within 24 h (Figure 3).MTP-PE AND OVARIAN CANCER XENOGRAFTS 401
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Figure 2 Photomicrographs of cytospin preparations of 3 day
post injection peritoneal washes from OS tumour bearing mice: a,
placebo liposome injected (arrows = tumour cells) and b, MTP-PE
liposome injected (arrow shows tumour cell). Inset = tumour cell
stained for HFMG2 surrounded by host peritoneal cells. (Space
bar = 100 lm).
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(P <.05). The majority of the peritoneal cells recruited by
injection of liposome preparations were polymorphonuclear
leucocytes. All 24 h these comprised 18%, 59%, and 74% of
PEC's in control mice after injection of PBS, placebo
liposomes or liposome encapsulated MTP-PE respectively,
and 42%, 75%, and 85% of PEC's in tumour bearing mice.
The total number of neutrophils at 24h was significantly
greater in tumour bearing mice than control mice (P <.05),
and within these groups both placebo liposomes and
liposome encapculated MTP-PE induced a greater neutrophil
influx than PBS (P <.05). However, there was no significant
difference between the changes noted in mice injected with
placebo liposomes or liposome encapsulated MTP-PE.
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Figure 3 Changes in total peritoneal cells and neutrophils in
mice injected with a, PBS (dotted lines), b, placebo liposomes
(open symbols) and c, MTP-PE liposomes (closed symbols).
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Combination therapy with rMU GM-SCF andliposome
encapsulated MTP-PE
Survival curves from two experiments with the LA and HU
xenografts, where therapy with GM-CSF and liposome
encapsulated MTP-PE was combined are shown in Figure 4
(a,b). An addictive effect on the survival duration of mice
with the HU xenograft was apparent in this experiment
(Figure 4a), mice receiving combination therapy surviving
significantly longer than those treated with MTP-PE or GM-
CSF alone (P <.05). Mice treated with rMu GM-CSF alone
did not show significantly prolonged survival compared to
PBSA treated mice. In the rapidly growing LA41 xenograft,
therapy with MTP-PE alone or GM-CSF alone had no
effect. Combination therapy led to significantly improved
survival (P <.01) suggesting a synergistic effect (Figure 4b).
The mice showing prolonged survival were not cured of
tumour, but eventually developed large intra-abdominal and
injection site tumours.
Discussion
The results presented here are the first to show the efficacy of
locally administered liposome-encapsulated MTP-PE in the
treatment of human cancer xenografts. Although the treat-
ment was effective in all three xenografts in terms of extend-
ing survival times of mice injected with tumours, there were
a Therapy
I M
100
Un
-0
100-
80 -
60 -
40 -
20 -
0 20 40 60 80 100
b Therapy
0 20 40 60 80
Days after tumour injection
Figure 4 The effect of combining therapy with GM-CSF and
MTP-PE lipsomes in the a HU xenograft and b, the LA xeno-
graft.
marked differences in the sensitivity to treatment between
different xenografts. Thus 80% of mice with the OS xeno-
graft were cured, whereas only a doubling of survival time
was seen in the early passages of the LA xenograft. At a later
passage when the LA xenograft was more aggressive, the
liposome-encapsulated MTP-PE was ineffective (Figure 4b).
This variation in susceptibility does not correlate to the
susceptibility to tumour necrosis factor (TNF). We have
shown that the OX xenograft is TNF-resistant, whereas mice
bearing the LA (including later passages) and HU tumours
show increased survival after injection of TNF intra-
peritoneally (Malik et al., 1989). MTP-PE must therefore
activate TNF independent tumouricidal mechanisms. Addi-
tionally we have been unable to show any biologically active
TNF production in the peritoneal lavage fluid from MTP-PE
treated mice, using a biological assay with a sensitivity of
1 pg ml-' TNF (Espevik & Niessen-Meyer 1986).
In order to elucidate the possible mechanism of action of
MTP-PE in these models, we studied the changes in peri-
toneal cell populations after intraperitoneal injections. In
murine ovarian cancer models in the antitumour effect of
Corynebacterium parvum has been linked to the influx of
neutrophils (Lichtenstein et al., 1984), and there is also in
vitro evidence that neutrophils can be cytotoxic for ovarian
cancer cells (Lichtenstein et al., 1989). For this reason we
studied the extent of neutrophil influx in mice injected intra-
peritoneally with liposome preparations. Both the placebo
and active liposomes led to an influx of neutrophils into the
peritoneal cavity in tumour bearing and control mice. How-
ever there were no significant differences were noted in either
the total number of peritoneal cells or the total number of
neutrophils following injection of placebo or active
liposomes. The extent of neutrophil infiltration does not
account for the difference in therapeutic efficacy of placebo
and active liposomes. The mechanisms underlying the in-
crease in peritoneal cell numbers after injection of liposome
preparations remain to be elucidated. Recent data have
shown that MDP can lead to the induction of GM-CSF and
M-CSF in mice (Broudy et al., 1990), but these cytokines are
unlikely to account for the rapid changes in peritoneal cell
populations seen in mice injected with liposome preparations
(Sayers et al., 1988).
As intraperitoneal or systemic administration of muramyl
dipeptide or its analogues do not increase NK cell activity in
the peritoneal cell population in mice (Talmadge 1985), we
have assumed that the therapeutic effects described here are a
consequence of the well documented effects of MTP-PE on
macrophage function (Sone et al., 1980, 1986b). This is also
suggested by the clustering ofperitoneal macrophages around
tumour cells seen after injection of liposome encapsulated
MTP-PE in to mice bearing the OS tumour. Cytokines
released by these macrophages, for example interleukin-1
may contribute to the antitumour effect of MPT-PE lipo-
somes.
Treatment of tumour bearing mice with recombinant GM-
CSF alone did not prolong survival in mice with the LA,
HU, or OS xenografts. The addition of GM-CSF to the
liposome regime led to a significant additive effect on the
survival of mice injected with either the LA or HU xeno-
grafts. In the OS xenograft, no additional effect was noted,
possibly because of the high cure rate achieved with liposome
encapsulated MTP-PE alone. We are unable to determine
whether the GM-CSF effect is due to a direct additive effect
on the antitumour activity of the resident peritoneal macro-
phages, or simply based on the generation of increased
numbers of tumouricidal macrophages. The tumour xeno-
grafts do not grow in vitro, and we are unable to perform in
vitro cytotoxicity assays to answer this question.
In conclusion these data show that intraperitoneal therapy
with liposome encapsulated MTP-PE can be added to the list
of potential 'biological' agents, such as TNF and interferons
(Balkwill et al., 1987; Manetta et al., 1989) and IL-2
stimulated killer cells (LAK cells) (Ortaldo et al., 1986), that
can be used in the treatment of ovarian cancer. Neither the
frequency, nor duration of liposome administration wereMTP-PE AND OVARIAN CANCER XENOGRAFTS 403
optimised in the present study, so that the results obtained
might still be improved. It is of some interest that liposome
encapsulated MTP-PE has also been shown to lead to
systemic activation of tumouricidal macrophages following
oral administration (Fidler et al., 1987). We have not how-
ever been able to show increased survival in the OS xenograft
this using an identical oral dose schedule that was used for
intraperitoneal therapy.
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